USE OF T-CELL IMMUNE RESPONSE CDNA 7 (TIRC7) IN ANGIOGENIC AND ANTI-ANGIOGENIC THERAPY

Details for Australian Patent Application No. 2002360946 (hide)

International Classifications

Event Publications

3 April 2003 Complete Application Filed

Priority application(s): 01 128 146.6 27.11.01 EP

21 August 2003 Application Open to Public Inspection

Published as AU-A-2002360946

12 August 2004 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

20 January 2005 Section 223 Application Received

UTKU, Nalan An application to extend the time from 27 Jun 2004 to 04 Nov 2004 in which to enter the national phase has been filed . Address for service in Australia - Cullen & Co 239 George Street Brisbane QLD 4000

17 March 2005 Section 223 Application Allowed

UTKU, Nalan The time in which to enter the national phase has been extended to 04 Nov 2004. Address for service in Australia - Cullen & Co 239 George Street Brisbane QLD 4000

2 February 2006 Assignment before Grant

Utku, Nalan The application has been assigned to GenPat77 Pharmacogenetics AG

27 April 2006 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.